+753.3%
MPC vs MRNA
+915.3%
-162.0%
-75.1%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.4% | -3.4% | +3.9% | +0.5% |
| 7D | +11.2% | -12.1% | +23.4% | +11.4% |
| 30D | -14.5% | -1.3% | -13.2% | -14.5% |
| 3M | +16.7% | +250.9% | -234.3% | +13.2% |
| 6M | +67.6% | +343.0% | -275.5% | +60.8% |
| YTD | +157.9% | +657.4% | -499.5% | +142.0% |
| 1Y | +116.7% | +794.9% | -678.3% | +101.8% |
| 3Y | +199.8% | +218.1% | -18.4% | +184.4% |
| 5Y | +604.4% | -3.4% | +607.8% | +580.5% |
| All | +753.3% | +915.3% | -162.0% | +600.9% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling